Clinical Trial

Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis

Recruiting
View on ClinicalTrials.gov →
Summary
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-14; most recent amendment 2026-05-07.
Status change: Active, Not Recruiting → Recruiting 2026-05-07
Trial Details
NCT Number NCT06885619
Lead Sponsor Beijing Anzhen Hospital
Collaborators: Beijing Jishuitan Hospital, Chinese Academy of Sciences
Conditions Left Ventricular Remodeling, Plasma Multi-Omics, Acute ST-segment Elevation Myocardial Infarction, Immunomics, Major Adverse Cardiovascular Events
Enrollment 1,000 participants
Start Date 2025-05-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12